NEW YORK and LONDON , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today
NEW YORK and LONDON , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today
NEW YORK and LONDON , Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today
- Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019 Phase I/II clinical study in patients with moderate-to-severe atopic keraconjunctivitis (AKC) announced June 2019 Further clinical data
Fast Track designation by the U.S. Food and Drug Administration ( FDA ) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designation follows a
New data from bullous pemphigoid (BP) patients and pemphigoid disease (PD) models generated by Dr. Christian Sadik’s group at University of Lubeck , Germany published in the August 2019 edition of JCI Insight (see link to article HERE ) Preclinical PD model shows maximal disease reduction by
NEW YORK and LONDON , July 31, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced an oral
NEW YORK and LONDON , June 28, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. Improvement in mean composite clinical efficacy score of 35% by Day 14 and 55% by Day 56. All patients were on maximal dosage of cyclosporin, the standard
Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP and AKC trials anticipated in 2019 Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic
